R406 free base是一种可口服的、ATP竞争性Syk抑制剂，Ki为30 nM，IC50为41 nM。
参考文献
[1] Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32(IF:16.562).
[2] Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 1;13(1):234-40. doi: 10.1158/1078-0432.CCR-06-1618(IF:8.911).
[3] Sun XC, Yan JY, Chen XL, et al. Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice. World J Gastroenterol. 2013 Apr 21;19(15):2340-7. doi: 10.3748/wjg.v19.i15.2340(IF:3.411).
[4] Ballinger ML, Ballinger ML, Hashimura K, et al. Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. J Cell Mol Med. 2010 Jun;14(6B):1408-18. doi: 10.1111/j.1582-4934.2009.00902.x(IF:4.6580).
-25~-15℃保存，有效期3年。
